Jerusalem, Israel.

This article presents a unique and novel approach for precision cancer medicine. It focuses on creating a ‘living biobank’ of 3D Tumor organoids, allowing the authors to perform large-scale drug testing on patient-derived tissue. Positive hits from these drug screens, i.e. drugs that could inhibit cancer growth most effectively, are validated in vivo, in a PDX-mice model system. If up scaled efficiently, these cancer models could reveal to clinicians many novel therapeutic opportunities, tailored to each patient’s individual tumor. This work nicely demonstrates the crucial need for better functional diagnostic tools, to overcome the challenges of translating genomic data into clinical impacts.

Read the full article at: